Corinfar retard 20 mg long-acting tablets 50

Size chart
Women's clothing size
Euro 32/34 36 38 40
USA 0/2 4 6 8
Bust(in) 31-32 33 34 36
Bust(cm) 80.5-82.5 84.5 87 92
Waist(in) 24-25 26 27 29
Waist(cm) 62.5-64.5 66.5 69 74
Hips(in) 34-35 36 37 39
Hips(cm) 87.5-89.5 91.5 94 99
How To Measure Your Bust

With your arms relaxed at your sides, measure around the fullest part of your chest.

How To Measure Your Waist

Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.

Volume discounts

Quantity Unit discount You Save
2 30% $12.96
3 35% $22.68
4 44% $38.02
 Customer ratings and reviews
Nobody has posted a review yet
in this language
Add to compare0
Add to wishlist
Active ingredient

Active substance: nifedipine 20 mg.

Excipients: lactose monohydrate - 31.6 mg, potato starch - 31.4 mg, microcrystalline cellulose - 31 mg, povidone K25 - 5.4 mg, magnesium stearate - 0.6 mg.

Composition of the film shell: hypromellose - 5.188 mg, macrogol 6000 - 0.861 mg, macrogol 35000 - 0.393 mg, quinoline yellow dye (E104) - 0.143 mg, titanium dioxide (E171) - 1.377 mg, talc - 1.038 mg.

Pharmacological properties

Selective slow calcium channel blocker (BMCC), a derivative of 1.4-dihydropyridine. It has an antianginal and hypotensive effect. Reduces the current of extracellular Ca 2+ inside cardiomyocytes and smooth muscle cells of the coronary and peripheral arteries; in high doses inhibits the release of Ca 2+ from intracellular depots. In therapeutic doses, normalizes transmembrane current Ca 2+ , impaired in a number of pathological conditions, primarily in arterial hypertension. Does not affect the tone of the veins. Enhances coronary blood flow, improves blood supply to myocardial ischemic zones without the development of the phenomenon of "theft", activates the functioning of collaterals. By expanding the peripheral arteries, it reduces the overall peripheral vascular resistance, myocardial tone, afterload and oxygen demand. It practically does not affect the sinoatrial and atrioventricular nodes, has antiarrhythmic activity. Increases renal blood flow, causes moderate natriuresis. The negative chrono-, dromo- and inotropic effect is overridden by reflex activation of the sympathoadrenal system and an increase in heart rate in response to peripheral vasodilation.

It's time onset of the clinical effect - 20 minutes, duration - 12 hours.

With prolonged use (2-3 months), tolerance to the action of the drug develops.

Indications for use
  • chronic stable angina (angina pectoris);
  • vasospastic angina (Prinzmetal angina, variant angina);
  • arterial hypertension.
  • hypersensitivity to nifedipine and other derivatives of 1,4-dihydropyridine or to other components of the drug;
  • arterial hypotension (systolic pressure below 90 mm Hg);
  • cardiogenic shock, collapse;
  • pronounced aortic stenosis;
  • chronic heart failure in the stage of decompensation;
  • unstable angina;
  • acute myocardial infarction (first 4 weeks);
  • I trimester of pregnancy;
  • lactation period;
  • joint use with rifampicin.

With caution: pronounced mitral valve stenosis, hypertrophic obstructive cardiomyopathy, severe bradycardia or tachycardia, SSSU, malignant arterial hypotension, hypovolemia, severe cerebral circulation disorders, myocardial infarction with left ventricular failure, gastrointestinal obstruction, renal and hepatic insufficiency, hemodialysis, II and III trimesters of pregnancy, children and adolescents under 18 years of age, simultaneous administration of beta-blockers, Digoxin.

Use in pregnancy and lactation
Contraindicated in pregnancy of the first trimester and during lactation. With caution: pregnancy (II and III trimesters).
Use in case of impaired liver function

With caution use in case of impaired liver function, with liver failure.

For patients with impaired liver function, careful monitoring is established; if necessary, the dose of the drug is reduced and / or other dosage forms of nifedipine are used.

Use in renal dysfunction

Use with caution in case of impaired renal function, with renal failure.

In patients with irreversible renal failure, who are on hemodialysis, who have high blood pressure and a reduced total amount of blood, the drug should be used carefully, since a sharp drop in blood pressure is possible.

Use in children
With caution: age up to 18 years.
Special instructions

During the treatment period, patients should refrain from taking ethanol.

It is recommended to stop treatment with the drug gradually.

It should be borne in mind that at the beginning of treatment may occur angina pectoris, especially after the recent abrupt cancellation of beta-blockers (the latter should be canceled gradually).

The simultaneous appointment of beta-blockers should be carried out under conditions of careful medical supervision, since this can cause an excessive decrease in blood pressure, and in some cases - an aggravation of the symptoms of heart failure.

With severe heart failure, the drug is dosed with great caution.

Diagnostic criteria for prescribing the drug for vasospastic angina are: the classic clinical picture, accompanied by an increase in the ST segment, the occurrence of ergonovin-induced angina pectoris or spasm of the coronary arteries, the detection of coronarospasm in angiography or the detection of an angiospastic component without confirmation (for example, at different voltage thresholds or with unstable angina, when electrocardiogram data indicate transient angiospasm).

For patients with severe obstructive cardiomyopathy, there is a risk of an increase in the frequency, severity and duration of angina attacks after taking nifedipine; in this case, it is necessary to cancel the drug.

In patients with irreversible renal failure who are on hemodialysis, have high blood pressure and reduced BCC, the drug should be used with caution, because a sharp drop in blood pressure is possible.

Patients with impaired liver function require careful monitoring; if necessary, the dose of the drug is reduced and / or other dosage forms of nifedipine are used.

If surgical intervention under anesthesia is necessary, it is necessary to inform the anesthesiologist about the treatment of the patient with nifedipine.

In extacorporeal fertilization, in some cases, BMCC caused changes in the head of spermatozoa, which can lead to impaired sperm function. In cases in which repeated extacorporeal fertilization did not occur for an unclear reason, the use of BMC, including nifedipine, can be considered a possible cause of failure.

During treatment, it is possible to obtain a false-positive result of a direct Coombs reaction and laboratory tests for antinuclear antibodies.

With the spectrophotometric determination of vanillyl-mandelic acid in the urine, nifedipine can be the cause of a false-inflated result, however, nifedipine does not affect the results of tests conducted with HPLC.

With caution, simultaneous treatment with nifedipine, disopyramide and flecainamide should be carried out due to the possible enhancement of the inotropic effect.

Influence on the ability to drive vehicles and control mechanisms

During the period of treatment, caution should be exercised when driving vehicles and engaging in other potentially dangerous activities that require increased concentration. attention and speed of psychomotor reactions.

Dosage and Administration

Inside, after eating, without chewing and drinking a sufficient amount of liquid.

The dose of the drug is selected by the doctor individually in accordance with the severity of the disease and the patient's sensitivity to the drug. For patients with concomitant severe cerebrovascular diseases and in elderly patients, the dose should be reduced.

Simultaneous food intake delays, but does not reduce the absorption of the active substance from the digestive tract.

The recommended dosing regimen is for adults.

Chronic stable and vasospastic angina

The drug is prescribed for 20 mg (1 tab.) 2 times / day. With an insufficiently pronounced clinical effect, the dose of the drug is gradually increased to 40 mg (2 tab.) 2 times / day. The maximum daily dose is 80 mg (4 tab./ day).

Essential hypertension

The drug is prescribed for 20 mg (1 tab.) 2 times / day. With an insufficiently pronounced clinical effect, the dose of the drug is gradually increased to 40 mg (2 tab.) 2 times / day. The maximum daily dose is 80 mg (4 tab./ day).

With a 2-fold prescription of the drug per day, the interval between doses should be an average of 12 h. The minimum interval between doses of the drug is at least 4 hours.

The duration of the course of treatment is determined by the attending physician.

In cases where the drug is used in high doses and / or for a long time, treatment should be discontinued gradually to avoid withdrawal syndrome.


Symptoms: loss of consciousness up to the development of coma, a drop in blood pressure, tachycardia or bradycardia, hyperglycemia, metabolic acidosis, hypoxia.

Treatment: artificial vomiting, gastric lavage, symptomatic therapy aimed at maintaining the activity of the cardiovascular system.

Side effects

From the cardiovascular system: tachycardia, arrhythmias, palpitations, peripheral edema (ankles, feet, legs), manifestations of excessive vasodilation (asymptomatic decrease in blood pressure, development or aggravation of heart failure, flushing of blood to the skin of the face, flushing of the skin of the face, feeling of heat), a pronounced decrease in blood pressure (rarely), syncope. In some patients, especially at the beginning of treatment or with an increase in the dose, angina attacks may occur, and in isolated cases - the development of myocardial infarction, which requires discontinuation of the drug.

From the nervous system: headache, dizziness, general weakness, increased fatigue, drowsiness. With prolonged use of the drug in high doses - paresthesia of the limbs, tremor, extrapyramidal (parkinsonian) disorders (ataxia, mask-like face, shuffling gait, tremor of the hands and fingers, difficulty swallowing), depression.

From the outside digestive system: dyspepsia (nausea, diarrhea or constipation), dry mouth, flatulence, increased appetite; rarely - gum hyperplasia, completely disappearing after discontinuation of the drug. With prolonged use - impaired liver function (intrahepatic cholestasis, increased activity of hepatic transaminases).

From the musculoskeletal system: arthritis, myalgia, swelling of the joints.

Allergic reactions: rarely - itching, urticaria, exanthema, autoimmune hepatitis, photodermatitis, anaphylactic reactions, exfoliative dermatitis.

From the hematopoietic system: anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura, agranulocytosis.

From the urinary system: an increase in daily diuresis in the first weeks of admission, deterioration of kidney function (in patients with renal failure).

Other: rarely - visual impairment (including transient blindness in C max nifedipine in plasma), gynecomastia (in elderly patients, completely disappearing after cancellation), galactorrhea, hyperglycemia, pulmonary edema, weight gain.

Storage conditions

The drug should be stored out of the reach of children, a place protected from light, at a temperature not exceeding 25 ° C.

Shelf life - 5 years.

Read more
Product Details

Data sheet

Dosage form
long-acting tablets
20 mg
Number of tablets
INN Russian
Russian title
Коринфар ретард
No comments

Be the first to write your review !



Create a free account to save loved items.

Sign in

Create a free account to use wishlists.

Sign in